drugset / Trial / NCT03957551
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NaSequentialOpen-labelTreatment
Summary
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
Timeline
- Start
- 2019-08-27
- Primary completion
- 2024-06-10
- Completion
- 2025-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |